synthetic time-series data for cross-institution use (finance; non-pharma) — referenced on Gretel's finance solutions page, dedicated case-study URL not directly resolved in this pass.
synthetic time-series data for cross-institution use (finance; non-pharma) — referenced on Gretel's finance solutions page, dedicated case-study URL not directly resolved in this pass.
The customer is anonymised in Gretel’s own case study — not withheld by us.
Gretel is a synthetic-data generation platform (acquired by NVIDIA) used to create privacy-preserving stand-ins for sensitive genomic and patient data.
This sits in the Design & Stress-Test stage of the AI use-case lifecycle: Named examples from the tools pharma teams use to scope, prototype and benchmark an AI use case before committing to build it — data-catalog, sandbox and evaluation platforms.
Published by Gretel on its own site, referenced in Gretel’s own case-study library without a standalone URL.
Related use cases
- 01used Gretel's synthetic-data platform to create safe synthetic genomic datasets, enabling genomics research and safe/private data sharing between researchers, healthcare providers and industry
- 02generated 16M+ synthetic patient records for labor-and-delivery data to train ML forecasting models while preserving privacy
- 03turned synthetic data into a strategic-growth capability (finance; non-pharma) — referenced on Gretel's finance solutions page, dedicated case-study URL not directly resolved in this pass.
- 04Novo Nordisk Transforms Clinical Trials With AI
- 05How Regeneron is discovering new treatments with AI
- 06How AI is changing drug discovery